Taysha gene therapies to release first quarter 2022 financial results and host conference call and webcast on may 16

Dallas, may 11, 2022 (globe newswire) -- taysha gene therapies, inc. (nasdaq: tsha), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing aav-based gene therapies for the treatment of monogenic diseases of the central nervous system (cns) in both rare and large patient populations, today announced that it will report its financial results for the first quarter ended march 31, 2022, and host a corporate update conference call and webcast on monday, may 16, 2022, at 8:00 am eastern time.
TSHA Ratings Summary
TSHA Quant Ranking